- Home
- ALV vs LEGN Comparison
ALV vs LEGN Comparison
Compare ALV & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALV
- LEGN
- Stock Information
- Founded
- ALV 1953
- LEGN 2014
- Country
- ALV Sweden
- LEGN United States
- Employees
- ALV N/A
- LEGN N/A
- Industry
- ALV Auto Parts:O.E.M.
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- ALV Consumer Discretionary
- LEGN Health Care
- Exchange
- ALV Nasdaq
- LEGN Nasdaq
- Market Cap
- ALV 9.7B
- LEGN 6.7B
- IPO Year
- ALV 1997
- LEGN 2020
- Fundamental
- Price
- ALV $126.51
- LEGN $33.88
- Analyst Decision
- ALV Buy
- LEGN Strong Buy
- Analyst Count
- ALV 9
- LEGN 12
- Target Price
- ALV $125.22
- LEGN $73.36
- AVG Volume (30 Days)
- ALV 516.2K
- LEGN 1.1M
- Earning Date
- ALV 10-17-2025
- LEGN 11-11-2025
- Dividend Yield
- ALV 2.69%
- LEGN N/A
- EPS Growth
- ALV 21.77
- LEGN N/A
- EPS
- ALV 9.16
- LEGN N/A
- Revenue
- ALV $10,462,000,000.00
- LEGN $796,838,000.00
- Revenue This Year
- ALV $3.65
- LEGN $70.75
- Revenue Next Year
- ALV $4.08
- LEGN $52.47
- P/E Ratio
- ALV $13.79
- LEGN N/A
- Revenue Growth
- ALV N/A
- LEGN 74.75
- 52 Week Low
- ALV $75.49
- LEGN $27.34
- 52 Week High
- ALV $127.89
- LEGN $52.31
- Technical
- Relative Strength Index (RSI)
- ALV 64.03
- LEGN 41.24
- Support Level
- ALV $124.26
- LEGN $32.70
- Resistance Level
- ALV $127.89
- LEGN $34.71
- Average True Range (ATR)
- ALV 1.89
- LEGN 1.18
- MACD
- ALV -0.10
- LEGN -0.06
- Stochastic Oscillator
- ALV 76.49
- LEGN 31.31
About ALV Autoliv Inc.
Autoliv Inc is the world-wide leader in passive safety components and systems for the auto industry. Products include seat belts, frontal air bags, side-impact air bags, air bag inflators, and steering wheels. The Renault-Nissan-Mitsubishi alliance is the company's largest customer at 10% of 2023 revenue, with Stellantis accounting for 10% and Volkswagen 9%. At 34% of 2023 revenue, the Americas was Autoliv's largest geographic region, followed by Europe at 27%, China at 20%, and rest of world at 19%.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.